In-use stability of reconstituted peptide solutions
What in-use period can be supported for a reconstituted research peptide solution?
§1Abstract
§1.1Review question
What in-use period can be supported for a reconstituted research peptide solution?
§1.2PICO frame
Table 1. The registered PICO frame. Any change made after protocol registration is recorded in the amendment log at §5 and is identified there as post hoc.
| Element | As registered |
|---|---|
| Population | Reconstituted peptide solutions stored under refrigeration or frozen. |
| Intervention | Storage time, temperature, diluent and freeze–thaw cycling. |
| Comparator | Time zero after reconstitution. |
| Outcomes | Chromatographic purity; aggregate content; pH; appearance; delivered content. |
§1.3Method in brief
A review of analytical and quality evidence for a compound or class as supplied, rather than of clinical effect. The protocol was registered with the Institute's secretariat before the search was executed. The search was run on 22 July 2024 across 8 sources and is reproduced in full at §2. Screening, extraction and certainty assessment were performed independently by two members of the secretariat with disagreement resolved by a third.[1,2]
§1.4Conclusion
Moderate certainty evidence, drawn from the formulation-science literature rather than from product-specific studies, indicates that freeze–thaw cycling of an unbuffered or phosphate-buffered peptide solution drives pH excursion and aggregation, that aggregation is not detected by a purity method alone, and that no in-use period can be supported without stability-indicating data on the actual presentation. Because such data exist for no research-supply presentation the Institute knows of, it publishes no in-use claim for any of them, and records that an approved lyophilised peptide product with full stability data claims as little as three hours.
The conclusion rests on 24 contributing studies, listed with their extracted data at §3 and summarised outcome by outcome at §4.
§1.5Limitations
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q1A(R2) Stability Testing of New Drug Substances and Products. ICH Harmonised Tripartite Guideline 2003;Step 4 version. identifier not held by the Institute
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research 2010;27(4):544–575. doi:10.1007/s11095-009-0045-6 · PMID 20143256
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.